Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2005-07-04
Product name
BONIVA(R) F. C. Tablets (100 mg)
1.2.1 Relevant identified uses
- Boniva is used in the treatment and prevention of osteoporosis in postmenopausal women
Icons in SDS
Company Information
company name
Hoffmann-La Roche Inc
e-mail address of the competent person responsible for the Safety Data Sheet
info.sds@roche.com
Section 2
SECTION 2: Hazards identification
OSHA Emergency Overview Form tablets Color white Hazard Overview - May cause gastrointestinal effects.
Potential health effects
Exposure: Ingestion - Target Organs: gastrointestinal system - Acute Effects: May cause gastrointestinal effects., Signs and symptoms may include nausea, vomiting, diarrhea, constipation, cramps, and loss of appetite.
Potential chronic health
No adverse effects known - Carcinogenicity: formulation not listed by NTP, IARC or OSHA - Carcinogenicity: IARC Gr3 not classifiable *1 Additional Health Information - Conditions Aggravated: Hypersensitivity to this material and other materials in its chemical class. Uncorrected hypocalcemia. Severe renal impairment. *1 referring to: Silicon dioxide colloidal (Aerosil 200, silica)
